NewAmsterdam Pharma appointed Robert W. Gunning as principal accounting officer, effective Aug. 10, 2026.
Gunning joined as vice president, controller. He succeeds Louise Kooij, who will depart effective Aug. 31, 2026.
He most recently served as interim controller and financial consultant at Altimmune from April 2026 to July 2026.
Earlier roles include vice president finance and corporate controller at Y-mAbs Therapeutics, and vice president controller at Excision Biotherapeutics.
NAMS•
